Biologics to raise CCM Duopharma's profile

A phamacist monitoring the production of injectable products at the company's biotech factory.

AS competition in its traditional businesses intensifies, CCM Duopharma Biotech Bhd (CCMD) is leveraging on a partnership with a South Korean pharmaceutical company to get a new source of revenue.

In a tie-up with PanGen Biotech Inc, CCMD is venturing into biological products, otherwise known as biologics. Clinical trials for a biosimilar erythopoietin (EPO) injectable drug to treat anemia in mainly renal failure patients.